In addition, synthetic activators or agonists for specific PTPN2 have not been identified in animal models of atherosclerosis, but further research may be required in the future, and this area of research will certainly facilitate the development of PTPN2 centered therapies that ultimately reduce the risk of atherosclerotic cardiovascular disease. Here, PTPN2 is linked to atherosclerosis.